SMAD3 and neoplasm: Minimal tumor formation in DSS-treated Smad3+/− compared to DSS-treated Smad3−/− mice suggests that the presence of at least one copy of SMAD3 is sufficient to protect mice from development of dysplasia and invasive carcinoma.